Francesco Meo - Fresenius CEO
| FSNUF Stock | USD 34.66 0.00 0.00% |
CEO
Dr. Francesco De Meo is Member of the Management Board and Chief Executive Officer of Business Segment Fresenius Helios at Fresenius SE Co KGaA since January 1, 2008. In 2000, Dr. De Meo became head of the legal and human resources departments of HELIOS Kliniken GmbH. On January 1, 2001, he was appointed to the HELIOS Kliniken Management Board with responsibilities for human resources, legal affairs, research and science. At the same time, he was also appointed Labor Relations Director. Before joining HELIOS, he was Director of Rauser AG, a management consultancy in Reutlingen, as well as a practicing Attorney. Currently, he serves as Chairman of the Supervisory Boards of Helios Beteiligungs AG and Helios Kliniken Schwerin GmbH. He studied Law and earned a Doctorate degree at Eberhard Karls Universitaet Tuebingen. since 2008.
| Age | 60 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Phone | 49 6172 608 2487 |
| Web | https://www.fresenius.com |
Fresenius Management Efficiency
The company has return on total asset (ROA) of 0.0292 % which means that it generated a profit of $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0793 %, meaning that it generated $0.0793 on every $100 dollars invested by stockholders. Fresenius' management efficiency ratios could be used to measure how well Fresenius manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 13 records | CEO Age | ||
| Javier Rodriguez | DaVita HealthCare Partners | 53 | |
| Steven Sell | agilon health | 58 | |
| Dirk Allison | Addus HomeCare | 68 | |
| Dirk CPA | Addus HomeCare | 68 | |
| Ernst Wastler | Fresenius SE Co | 65 | |
| Paul Kusserow | Amedisys | 63 | |
| Caroline Grace | AMN Healthcare Services | 55 | |
| Brent CFA | Regional Health Properties | 48 | |
| Heath CPA | ModivCare | 53 | |
| Christopher Christensen | The Ensign Group | 55 | |
| Richard Ashworth | Amedisys | 49 | |
| Christopher Reading | US Physicalrapy | 60 | |
| Susan Salka | AMN Healthcare Services | 56 | |
Management Performance
| Return On Equity | 0.0793 | |||
| Return On Asset | 0.0292 |
Fresenius SE Leadership Team
Elected by the shareholders, the Fresenius' board of directors comprises two types of representatives: Fresenius inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius' management team and ensure that shareholders' interests are well served. Fresenius' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesco Meo, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Helios | ||
| Michael Sen, Pres CEO | ||
| Sara Hennicken, Chief Officer | ||
| Helen Giza, Member SE | ||
| Ernst Wastler, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Vamed | ||
| Sebastian Biedenkopf, HR, Officer | ||
| Matthias Link, Sr Communications | ||
| Markus Georgi, Senior Vice President Investor Relations | ||
| Carla Kriwet, Members SE |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresenius a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0793 | |||
| Return On Asset | 0.0292 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 43.74 B | |||
| Shares Outstanding | 563.24 M | |||
| Shares Owned By Insiders | 26.90 % | |||
| Shares Owned By Institutions | 36.39 % | |||
| Price To Earning | 7.29 X | |||
| Price To Book | 0.71 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Fresenius Pink Sheet
Fresenius financial ratios help investors to determine whether Fresenius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fresenius with respect to the benefits of owning Fresenius security.